289 patents
Utility
Uses of Chimeric Antigen Receptor (Car) T-cell Therapies In Combination with Inhibitors of Inflammation-related Soluble Factors
18 Jan 24
Provided herein are uses of chimeric antigen receptors (CARs) for treating a cancer (such as B cell related cancer, e.g., multiple myeloma).
Ethan Greene THOMPSON, Shari m. KAISER, Nathan Thomas MARTIN
Filed: 3 Dec 21
Utility
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
16 Jan 24
Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
Filed: 16 Aug 21
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
9 Jan 24
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate.
Jerry Lee Atwood
Filed: 1 Oct 20
Utility
Car T Cell Therapy In Patients Who Have Had Prior Anti-cancer Alkylator Therapy
14 Dec 23
Provided herein are uses of chimeric antigen receptors (CARs) for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma).
Julie Ann RYTLEWSKI, Afshin MASHADI-HOSSEIN, Timothy CAMPBELL, Jaymes FULLER
Filed: 3 Nov 21
Utility
T lymphocyte production methods and t lymphocytes produced thereby
5 Dec 23
Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation.
Bitao Liang, Xiaohua Lu, Wei Liu, Kathy E. Karasciewicz-Mendez, Christopher Wiwi, Kruti Shah
Filed: 29 Dec 16
Utility
Crystalline (R)-5-CARBAMOYLPYRIDIN-3-YL-2-METHYL-4-(3-(TRIFLUOROMETHOXY)BENZYL)PIPERAZINE-1-CARBOXYLATE, Compositions and Methods of Use Thereof
30 Nov 23
Provided herein are crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate.
Lianfeng Huang, Nancy Tsou, Nicole Suzanne White, Jun Xu, Qun Zhang
Filed: 5 May 23
Utility
Bispecific Antibody Treatment of Lymphoid Malignant Neoplasm Conditions
16 Nov 23
Provided is a method for the treatment of a lymphoid malignant neoplasm in a subject in need thereof comprising administering to the subject an effective amount of a bispecific antibody which comprises a Fab portion that binds CD47 and a Fab portion that binds CD20.
Haralambos HADJIVASSILIOU, Dan ZHU, Jeonghoon SUN, Sharmistha ACHARYA, Jeffrey JOHNSON, Kandasamy HARIHARAN, Ho CHO
Filed: 5 Oct 21
Utility
Treatment of cardiovascular disease using ActRII ligand traps
14 Nov 23
Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.
Keith Hruska, Yifu Fang, William Smith, Nianhang Chen
Filed: 8 Oct 15
Utility
Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
7 Nov 23
Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized.
Stewart Abbot, Tianjian Li, Bitao Liang
Filed: 5 Mar 21
Utility
Solid Forms Comprising (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE and Salts Thereof, and Compositions Comprising and Methods of Using the Same
26 Oct 23
Provided herein are formulations, processes, solid forms and methods of use relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.
Lianfeng Huang, Wenju Wu
Filed: 23 Jan 23
Utility
Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE
26 Oct 23
A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Maria Soraya Carrancio Anton, Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, SR., Gang Lu, Daniel W. Pierce, Lilly L. Wong
Filed: 29 Jun 23
Utility
Antiproliferative Compounds and Second Active Agents for Combined Use
19 Oct 23
Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma.
Lilly L. Wong
Filed: 25 Apr 23
Utility
Anti-CD47 antibodies and uses thereof
17 Oct 23
Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47.
Aaron Sato, Ryan Stafford, Junhao Yang
Filed: 29 Oct 20
Utility
Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein
10 Oct 23
Provided herein are methods and intermediates for making (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Terrence Joseph Connolly, Hon-Wah Man
Filed: 3 Nov 21
Utility
Pharmaceutical compositions comprising (s)-4-(4-(4- (((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrtle and methods of using the
10 Oct 23
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Filed: 8 Jan 20
Utility
Activin-actrii Antagonists and Uses for Treating Bone and Other Disorders
21 Sep 23
Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment.
Victoria Sung, Randall Stevens, William Smith, Victor Schorr Sloan, Keith Hruska, Yifu Fang
Filed: 18 Jan 23
Utility
Pharmaceutical Compositions Comprising (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE and Methods of Using the Same
14 Sep 23
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Sreenivas S. Bhat, Fabien Boulineau, Donna Carroll, Tracy Lee Gaebele, Yuchuan Gong, Isabel Minjung Hong, Zhengmao Li, Ye Tian
Filed: 7 Nov 22
Reissue
Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
12 Sep 23
Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein.
Darshan Parikh, Anil Menon
Filed: 23 Sep 20
Utility
Combination Therapy for the Treatment of Cancer
7 Sep 23
Provided herein are methods of treating and/or managing cancers, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in combination with daratumumab.
Michael D. Amatangelo, Chad Bjorklund, Anjan Thakurta, Xiankang Hong, Mariana Cota
Filed: 9 Nov 22
Utility
Methods of Treating Hematological Malignancies Using 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DION
7 Sep 23
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, for treating, preventing or managing hematological malignancies.
Maria Soraya Carrancio Anton, Tonia J. Buchholz, Shailaja Kasibhatla, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
Filed: 10 May 23